BioNTech and partner Duality Biologics revealed positive interim results from a phase III trial of their HER2-targeting antibody-drug conjugate (ADC) for HER2-positive breast cancer, achieving the primary endpoint of progression-free survival. The outcome positions the ADC as a strong competitor to existing therapies, potentially leading to regulatory submissions globally, including in China. This success marks BioNTech’s first phase III oncology milestone, reinforcing its immuno-oncology pipeline.